COPENHAGEN Feb 22 Danish biotech drugmaker
Genmab's Darzalex, which is used to fight cancer in
bone marrow and marketed by Johnson & Johnson, has the
potential to achieve annual peak annual sales as high as $13
billion, its chief executive told Reuters.
"It could work in other blood cancers as well as in solid
tumours. So that means $13 billion potential if it would work in
all the indications, Jan van de Winkel said on Wednesday.
He acknowledged that $13 billion would be the most rosy
scenario but said that Darzalex could "definitely" achieve more
than $9 billion.
Genmab expects sales of Darzalex to surpass $1 billion this
year, the company said on Wednesday.
(Reporting by Stine Jacobsen; Editing by David Goodman)